- Home
- OCUL vs IDYA Comparison
OCUL vs IDYA Comparison
Compare OCUL & IDYA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OCUL
- IDYA
- Stock Information
- Founded
- OCUL 2006
- IDYA 2015
- Country
- OCUL United States
- IDYA United States
- Employees
- OCUL N/A
- IDYA N/A
- Industry
- OCUL Biotechnology: Pharmaceutical Preparations
- IDYA Biotechnology: Pharmaceutical Preparations
- Sector
- OCUL Health Care
- IDYA Health Care
- Exchange
- OCUL Nasdaq
- IDYA Nasdaq
- Market Cap
- OCUL 2.3B
- IDYA 2.3B
- IPO Year
- OCUL 2014
- IDYA 2019
- Fundamental
- Price
- OCUL $11.48
- IDYA $32.18
- Analyst Decision
- OCUL Strong Buy
- IDYA Buy
- Analyst Count
- OCUL 9
- IDYA 17
- Target Price
- OCUL $22.63
- IDYA $48.20
- AVG Volume (30 Days)
- OCUL 3.1M
- IDYA 1.3M
- Earning Date
- OCUL 11-04-2025
- IDYA 11-04-2025
- Dividend Yield
- OCUL N/A
- IDYA N/A
- EPS Growth
- OCUL N/A
- IDYA N/A
- EPS
- OCUL N/A
- IDYA N/A
- Revenue
- OCUL $56,664,000.00
- IDYA $7,000,000.00
- Revenue This Year
- OCUL N/A
- IDYA $90.17
- Revenue Next Year
- OCUL $17.75
- IDYA $219.42
- P/E Ratio
- OCUL N/A
- IDYA N/A
- Revenue Growth
- OCUL N/A
- IDYA N/A
- 52 Week Low
- OCUL $5.79
- IDYA $13.45
- 52 Week High
- OCUL $13.85
- IDYA $33.64
- Technical
- Relative Strength Index (RSI)
- OCUL 45.90
- IDYA 67.18
- Support Level
- OCUL $11.38
- IDYA $28.17
- Resistance Level
- OCUL $11.78
- IDYA $33.64
- Average True Range (ATR)
- OCUL 0.50
- IDYA 1.68
- MACD
- OCUL -0.01
- IDYA 0.40
- Stochastic Oscillator
- OCUL 30.89
- IDYA 80.76
About OCUL Ocular Therapeutix Inc.
Ocular Therapeutix Inc is a biotechnology company that specializes in therapies for diseases and conditions of the eye. The company uses its proprietary hydrogel platform technology to deliver therapeutic agents to the eye. Its pipeline consists of eye medication that aims to overcome the limitations of current eye-drop-based therapies for ophthalmic diseases and conditions. Its pipeline product includes Dextenza, OTX-TIC, OTX-TKI, and OTX-IVT.
About IDYA IDEAYA Biosciences Inc.
IDEAYA Biosciences Inc is an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. Its approach integrates small molecule drug discovery with extensive capabilities in identifying and validating translational biomarkers to develop targeted therapies for select patient populations that are likely to benefit from these targeted therapies. The company's clinical-stage product candidates include darovasertib (PKC), IDE397 (MAT2A), IDE849 (DLL3), IDE275/GSK959 (Werner Helicase), IDE161 (PARG), and IDE705/GSK101 (Pol Theta Helicase). In addition, it also working on other development candidates and has multiple earlier-stage preclinical programs.